NorthWest Biotherapeutics Inc (NWBO)

[Virgilio]

Two key points:

"The median overall survival for patients receiving standard of care therapy is approximately 15 months and the average five-year survival rate is less than three percent."

and

"Under a May 2017 agreement between Inovio and Regeneron, the combination trial will be solely conducted and funded by Inovio"

it IMO seems once more like if these combo trials won't bring any upfront money for partnerships at the immuno-oncology companies. Not a good thing. This might explain why in my opinion all combo trials seem not to have started yet, waiting for results (and possibly partnership thereafter with upfront money) for PIII L trial.